Business Wire

Terralpha harnesses ADVA TeraFlex™ for 600G transport throughout France

27.1.2022 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Terralpha has deployed its FSP 3000 TeraFlex™ terminal to transport data at speeds up to 600Gbit/s between cities across France. The solution enables Terralpha – the new service provider arm of France’s SNCF railway group – to use its spare fiber capacity to offer low-latency, ultra-high-speed connectivity to customers. Now, enterprises, mobile network operators and government institutions can leverage flexible, highly reliable services for edge computing and 5G applications. What’s more, Terralpha’s network will enable homes and businesses in many underserved areas to access next-generation broadband and mobile connectivity. The new solution also features ADVA’s FSP 3000 OLS, flexgrid multi-degree ROADMs, its ALM fiber monitoring technology and its Ensemble Controller network management and control solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005706/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s TeraFlex™ technology is helping Terralpha to drive 600G connectivity throughout France. (Photo: Business Wire)

“With around 20,000km of fiber deployed alongside our railway infrastructure, we knew we were in a unique position to offer super-fast connectivity right across France. What we needed was a transport solution with the capacity, flexibility and scale to match our ambitions and a partner we could trust. In ADVA, we have a European technology provider with a wealth of experience and an excellent track record for success,” said Gabriel Chenevoy, CEO of Terralpha. “The ADVA team has worked with us to deliver a solution that maximizes the value of our existing network and empowers us to provide our customers with a new level of bandwidth capacity and service quality. Our backbone infrastructure will be key to closing the digital divide by delivering high-speed services in a highly efficient and sustainable way to around 100 tier 3 cities within two years. The performance of ADVA’s equipment combined with our straight and diverse routes has enabled us to reduce actual latencies between major cities in France from 10% to 40%, supporting new latency-sensitive applications.”

The ADVA FSP 3000 TeraFlex™ terminal is specifically designed to inject enormous capacity into deployed networks without operators having to spend significant amounts on overhauling their infrastructure. With its software-defined fractional QAM modulation and adaptive baud rate capabilities, the low-power 1RU terminal is now ensuring optimal spectrum utilization in Terralpha’s transport system. The network is managed by ADVA’s Ensemble Controller, which supports programmatic SDN control, further improving efficiency by reducing troublesome and time-consuming manual processes. The infrastructure is also continuously assured by ADVA’s ALM fiber monitoring technology with precise fault localization from Ensemble Fiber Director. This enables Terralpha’s maintenance teams to quickly detect and pinpoint any degradation in the fiber plant and resolve issues before services are affected.

“We’re helping Terralpha to unlock the full value of its fiber assets. By harnessing our technology and the expertise of our engineers, Terralpha can take advantage of its vast network architecture to bring reliable, low-latency services at unprecedented speeds to homes, businesses and service provider customers in every corner of France,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “One of the keys to the success of this project has been our close collaboration with the Terralpha team to make sure the new solution meets their exact requirements. That’s helped us deliver a turnkey solution that works seamlessly with Terralpha’s existing network to provide optimal performance over every single link. With our scalable technology and continuing support, there’s no limit to what Terralpha can achieve.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Terralpha

Incorporated in 2021, Terralpha, a 100% subsidiary of SNCF Réseau, offers Ultra High Speed data transport services. Its DNA “Ultra High Speed for all territories” is supported by an ambition to deploy Ultra High Speed and high reliability points of presence throughout France. The choice of architecture and transmission equipment, of European origin, enables to create circuits between cities at speeds of 100Gb/s to 600Gb/s at very low latency.

Terralpha’s mission is to ensure the trusted routing of data traffic through fully owned active and passive infrastructure. Additionally, and in order to facilitate the development of regional data centers, Terralpha offers a range of hosting solutions called ”Digital Tiles” to host the equipment necessary for the storage and the processing of information locally. Each of these “Digital Tiles” has a dual fiber connection to the Terralpha network, and to the public networks to meet the strategic requirements of data centers. www.terralpha.fr

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

For Terralpha press:
Hervé Legay
t +33 1 84 21 15 07
contact@terralpha.fr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye